FIELD: medicine. SUBSTANCE: method involves administering therapeutically efficient quantity of (S)-oxibutinine or (S)- desethyloxibutinine or its pharmaceutically permissible salt essentially free from the corresponding R enantiomorph. Pharmaceutical compositions are prepared as tablets and transcutaneous preparations containing (S)-oxibutinine or (S)- desethyloxibutinine and permissible carrier. Desethyloxibutinine synthesis is described. EFFECT: prevented negative treatment results accompanying racemic oxibutinine administration. 31 cl, 1 dwg, 10 tbl
Authors
Dates
2002-04-27—Published
1996-01-25—Filed